

# Systemic immune-inflammation index: A new indicator of predicting 1-, 2-and 3-year disease-free survival of patients with colon cancer

Lu Zhang<sup>1,A–D</sup>, Zhong Zhang<sup>1,C</sup>, Haochun Guo<sup>1,B</sup>, Bin Huang<sup>2,F</sup>, Haijun Zhang<sup>1,E,F</sup>

<sup>1</sup> Department of Oncology, Zhongda Hospital, Medical School of Southeast University, Nanjing, China

<sup>2</sup> Comprehensive Cancer Center of Nanjing Drum Tower Hospital, Affiliated Hospital of Nanjing University Medical School & Clinical Cancer Institute of Nanjing University, Clinical College of Nanjing Medical University & Clinical College of Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine & Medical School of Southeast University, China

A – research concept and design; B – collection and/or assembly of data; C – data analysis and interpretation;

D – writing the article; E – critical revision of the article; F – final approval of the article

Advances in Clinical and Experimental Medicine, ISSN 1899–5276 (print), ISSN 2451–2680 (online)

*Adv Clin Exp Med.* 2023;32(1):13–22

## Address for correspondence

Haijun Zhang

E-mail: haijunzhang@seu.edu.cn

## Funding sources

None declared

## Conflict of interest

None declared

Received on February 12, 2022

Reviewed on June 28, 2022

Accepted on August 17, 2022

Published online on October 11, 2022

## Cite as

Zhang L, Zhang Z, Guo H, Huang B, Zhang H. Systemic immune-inflammation index: A new indicator of predicting 1-, 2-and 3- year disease-free survival of patients with colon cancer. *Adv Clin Exp Med.* 2023;32(1):13–22. doi:10.17219/acem/152826

## DOI

10.17219/acem/152826

## Copyright

Copyright by Author(s)

This is an article distributed under the terms of the Creative Commons Attribution 3.0 Unported (CC BY 3.0) (<https://creativecommons.org/licenses/by/3.0/>)

## Abstract

**Background.** The systemic immune-inflammation index (SII) is a useful prognostic indicator for some types of cancer, but it remains to be elucidated if it is similarly useful for colon cancer.

**Objectives.** This study aims to investigate the prognostic value of preoperative SII in patients with colon cancer undergoing radical surgery.

**Materials and methods.** The clinical materials of 188 patients with colon cancer who underwent radical surgery from September 1, 2013, to August 31, 2018, in Zhongda Hospital at Southeast University (Nanjing, China) were collected retrospectively. The SII was calculated as platelet count  $\times$  neutrophil count / lymphocyte count. All patients enrolled in the study were then assigned into 2 different groups according to the median value of SII for comparison of clinical features between the 2 groups. The survival curve was drawn using the Kaplan–Meier method. Univariate and multivariate analysis were performed using the Cox regression model, analyzing the independent risk factors. The independent factors were analyzed with the R software to construct a nomogram of 1-, 2- and 3-year disease-free survival (DFS) after operation. Lastly, a web-based probability calculator was constructed to dynamically predict the possibility of DFS of patients.

**Results.** The SII could significantly predict DFS of patients with colon cancer with the median value of 514.13xs. For DFS, multivariate Cox analysis indicated that age, tumor location, pathological N stage, and preoperative SII level were independent risk factors for patients with colon cancer after radical resection ( $p < 0.05$ ). A nomogram and a web-based probability calculator were constructed based on these factors.

**Conclusions.** The preoperative SII level can predict DFS in patients who received radical surgery with colon cancer. The nomogram constructed based on independent risk factors is helpful in predicting DFS of colon cancer patients in clinical practice.

**Key words:** prognosis, colon cancer, nomogram, systemic immune-inflammation index

## Background

Colorectal cancer is one of the most prevalent malignant tumors of the digestive tract worldwide. According to the World Health Organization (WHO) International Agency for Research on Cancer (IARC) global burden of cancer estimates for 2020, there were over 1.9 million new cases of colorectal cancers (including anal) and 935,000 deaths in 2020, accounting for roughly 1/10 of all cancer cases and deaths.<sup>1</sup> In China, colon cancer ranked 2<sup>nd</sup> and 5<sup>th</sup> in terms of new cases and deaths among the top 10 malignancies in 2020.<sup>1</sup> With the advance in treatments in recent years, the 5-year survival rate for colon cancer in China has risen to 57.6%; however, there is still room for improvement.<sup>2</sup> At present, surgery is the most common treatment for resectable colon cancer. However, the postoperative local recurrence and distant metastasis rate are still very high, owing to the anatomical structure of the colon and the characteristics of cancer itself. Local recurrence and distant metastasis are the main causes of decreased survival time and the decline in quality of life.<sup>3</sup> Therefore, to promote good health and prevent mortality, it is critical to assess the recurrence risk and survival time of patients with colon cancer after radical resection. According to previous research, inflammation is vital in various stages of tumor incidence, tissue invasion and metastasis.<sup>4</sup> In recent years, various inflammatory indicators have been presented for predicting tumor prognosis in order to increase the overall survival (OS) rate of patients with cancer, such as platelet-to-lymphocyte ratio (PLR), neutrophil-to-lymphocyte ratio (NLR)<sup>5</sup> and lymphocyte-to-monocyte ratio (LMR).<sup>6</sup> Systemic immune-inflammation index (SII), which is equal to platelet count  $\times$  neutrophil count / lymphocyte count ( $P \times N/L$ ), could more thoroughly indicate the state of inflammation in the body based on a combination of the aforementioned 3 indicators of platelet, neutrophil and lymphocyte. So far, SII has demonstrated predictive value for prognosis in gastric cancer,<sup>7</sup> bladder cancer<sup>8</sup> and breast cancer.<sup>9</sup> However, its predictive value for the prognosis of colon cancer remains unknown.<sup>10</sup>

## Objectives

To this end, this study aimed to investigate the predictive value of preoperative SII level for disease-free survival (DFS) of colon cancer patients undergoing radical surgery, and to construct a nomogram that could be used as a simple prognostication tool in clinical care.

## Materials and methods

### Patients

From September 1, 2013, to August 31, 2018, patients with colon cancer who were admitted to Zhongda

Hospital at Southeast University (Nanjing, China) and received radical surgery were recruited into the study. The inclusion criteria were as follows: 1) radical surgery received; 2) postoperative pathological confirmation of colon cancer; 3) preoperative imaging showing no distant metastasis. Exclusion criteria were as follows: 1) patients who had received neoadjuvant therapy such as radiotherapy, chemotherapy and immunotherapy before surgery; 2) patients with severe cardiopulmonary insufficiency, severe infections, blood system diseases, autoimmune disease, hepatitis, or other tumors before surgery; 3) cases lacking crucial clinical or follow-up data. Finally, a total of 188 eligible cases were included in the study after application of the inclusion and exclusion criteria.

This study retrospectively collected the data of previous cases for anonymous analysis without exposing privacy information of patients, so informed consent could be waived. It was carried out in accordance with the Declaration of Helsinki.

### Collection of clinical data

The temperature of all patients was normal 3 days before surgery, without obvious symptoms of local or systemic infection. Venous blood was collected 1 week before surgery, and SII for each patient was calculated using the formula  $SII = P \times N/L$ . Clinical data (including age, gender, preoperative carcinoembryonic antigen (CEA) level, and preoperative intestinal obstruction) and pathological data (including tumor location, histological type, the maximum diameter, vascular and nerve invasion, the number of dissected lymph nodes, TNM staging, and human epidermal growth factor receptor-2 (HER2) expression) were collected for analysis. Right-sided colon cancer included cecum cancer, ascending colon cancer and right-half transverse colon cancer, while the rest were considered left-sided colon cancer. The follow-up started on the day of surgery (either in hospital or outpatient) and was performed every 3–6 months for the first 2 years, and then every 6 months thereafter. The deadline for follow-up was August 31, 2021. The patient's DFS during follow-up was recorded.

### Evaluation criteria

The time from the postoperative period until the first recurrence or death due to recurrence or termination of follow-up was referred to as DFS. Postoperative recurrence was defined as the recurrence of malignant tumors related to the primary focus in all organs after radical resection, including local recurrence and distant metastasis. Local recurrence was understood as recurrence in the pelvic region, whereas distant organ metastasis referred to recurrence outside of the pelvic region. Postoperative recurrence was confirmed with imaging or pathology.

## Statistical analyses

The IBM SPSS v. 26.0 software (IBM Corp., Armonk, USA) was used for statistical analysis. The SII scores were divided into a low and a high group according to the median. The  $\chi^2$  test or Fisher's exact test were used for comparison between groups. The Kaplan–Meier method was used for survival analysis and the log-rank test were used to compare the differences between the low and high groups. Univariate and multivariate Cox regression model was used to analyze risk factors that impacted the prognosis of patients with colon cancer. Some data regarding preoperative CEA, vascular invasion, nerve invasion, and HER2 expression were missing. In order to avoid the reduction of statistical test efficiency and bias caused by the missing data, multiple interpolation was used to compensate for missing data. Multiple interpolation would generate 5 interpolated datasets, each containing data of 188 patients, without missing items.

These 5 datasets and the original dataset underwent independent Cox analysis to provide 6 survival functions. The 6 survival functions were in good agreement, indicating that the additional data did not cause obvious bias in the results. Therefore, the best-performing dataset was chosen as the final data for analysis. Bilateral probability test was used for all statistics and  $p < 0.05$  was considered statistically significant. The nomogram to predict 1-, 2- and 3-year DFS of patients after operation and the web-based probability calculator were constructed with the R software v. 4.1.1 (R Foundation for Statistical Computing, Vienna, Austria). The bootstrap method was used to repeat sampling 1000 times, serving to perform the internal validation of the nomogram. The receiver operating characteristic (ROC) curve and C-index were used to assess the differentiation and accuracy of the predictive model, and a calibration curve was used to evaluate the consistency of the prediction model of the nomogram. The flowchart (Fig. 1) depicts the concept for this study.




Fig. 1. Flowchart of the study

SII – systemic immune-inflammation index.

## Results

### General clinical characteristics of the patients

A total of 188 patients were included. There were 117 males and 71 females, whose age ranged from 33 to 92 years, with a median age of 67 years. Preoperative CEA level was  $\geq 5$  ng/mL in 93 patients and  $< 5$  ng/mL in 81 patients. Preoperative ileus was present in 50 cases. One hundred and seven patients had the tumor in the left colon, while 81 patients had tumors in the right colon. The tumor diameter in 123 patients was  $\leq 5$  cm.<sup>11</sup> The number of cases with adenocarcinoma, mucinous adenocarcinoma and other histological types were 148, 9 and 31, respectively. Vascular invasion was observed in the specimens of 65 patients, while 33 patients did not present with invasion. The number of patients with TNM stage I (including T0), stage II and stage III was 9, 93

and 86, respectively. The median follow-up time of all patients was 1294 (206–2766) days, during which 63 patients developed postoperative recurrence, including 11 cases with local recurrence and 52 cases with distant metastasis; 16 patients died. Among the patients with distant metastasis, 36 cases were liver metastasis, while the remaining 16 patients presented with multiple metastasis or single metastasis in other sites. Generally, the postoperative recurrence and mortality rate were 33.5% and 8.5%, respectively. The median value of the preoperative SII was 514.13, ranging from 108.27 to 5596.89. The clinical characteristics of the enrolled patients are presented in Table 1.

### Correlation between preoperative SII and clinical variables

The clinical data and characteristics of the patients were compared between the 2 groups. (Table 2). There were

**Table 1.** Baseline characteristics of patients

Variables	Characteristics	Numbers of patients (n, %)
Gender	male	117 (62.2)
	female	71 (37.8)
Age [years]	$< 65$	76 (40.4)
	$\geq 65$	112 (59.6)
Preoperative CEA [ng/mL]	$< 5$	93 (49.5)
	$\geq 5$	81 (43.1)
	unknown	14 (7.4)
Preoperative ileus	yes	50 (26.6)
	none	138 (73.4)
Tumor location	left-sided colon	107 (56.9)
	right-sided colon	81 (43.1)
Diameter [cm]	$\leq 5$	123 (65.4)
	$> 5$	65 (34.6)
Histology	adenocarcinoma	148 (78.7)
	mucinous adenocarcinoma	9 (4.8)
	others	31 (16.5)
Vascular invasion	yes	65 (34.6)
	none	121 (64.4)
	unknown	2 (1.1)
Nerve invasion	yes	33 (17.6)
	none	152 (80.9)
	unknown	3 (1.6)
Number of dissected peri-intestinal lymph nodes	$< 12$	42 (22.3)
	$\geq 12$	146 (77.7)
HER2 expression	0/1+	112 (59.6)
	2+/3+	70 (37.2)
	unknown	6 (3.2)
T stage	1–2 (including Tis)	14 (7.4)
	3	163 (86.7)
	4	11 (5.9)
N stage	0	100 (53.2)
	1	59 (31.4)
	2	29 (15.4)
TNM stage	I (including T0)	9 (4.8)
	II	93 (49.5)
	III	86 (45.7)

CEA – carcinoembryonic antigen; HER2 – human epidermal growth factor receptor 2.

**Table 2.** Characteristics of patients from different SII groups

Characteristics	SII		$\chi^2$	p-value
	low group (n = 94)	high group (n = 94)		
Gender (male/female)	61/33	56/38	0.566	0.452
Age (<65/≥65 years)	36/58	40/54	0.353	0.552
Preoperative CEA (<5/≥5 ng/mL)	54/40	48/46	0.772	0.380
Preoperative ileus (yes/no)	20/74	30/64	2.725	0.099
Tumor location (left colon/right colon)	56/38	51/43	0.542	0.461
Diameter (≤5/>5 cm)	71/23	52/42	8.489	<b>0.004</b>
Histology (adenocarcinoma/mucinous adenocarcinoma/others)	75/3/16	73/6/15	1.401	0.713
Vascular invasion (yes/no)	27/67	38/56	2.845	0.092
Nerve invasion (yes/no)	15/79	19/75	0.574	0.448
Number of dissected peri-intestinal lymph nodes (<12/≥12)	24/70	18/76	1.104	0.293
HER2 expression (0 and 1+/2+ and 3+)	61/33	54/40	1.097	0.295
T stage (1–2 (including Tis)/3/4)	9/83/2	5/80/9	5.653	0.059
N stage (0/1/2)	53/27/14	47/32/15	0.818	0.664
TNM stage (I (including T0)/II/III)	6/48/40	3/45/46	1.485	0.467

SII – systemic immune-inflammation index; CEA – carcinoembryonic antigen; HER2 – human epidermal growth factor receptor 2. The  $\chi^2$  test was used for the comparison between the 2 groups. Values in bold are statistically significant.

statistical differences in tumor diameter in the 2 groups ( $p < 0.05$ ), while gender, age, preoperative CEA level, intestinal obstruction, tumor location, tumor histology, vessel and nerve invasion, number of dissected peri-intestinal lymph nodes, HER2 expression, and T, N and TNM stage did not differ between the 2 groups ( $p > 0.05$ ).


### Risk factors affecting the prognosis of colon cancer patients receiving radical resection

As shown in Table 3, SII, as well as age, preoperative CEA level, tumor location, vascular and nerve invasion, and N and TNM stage affected the DFS of colon cancer in the 2 groups. Multivariate Cox analysis indicated that

age, tumor location, pathological N stage, and preoperative SII level were independent risk factors for DFS of patients who received radical resection of colon cancer. The Kaplan–Meier method indicated that there was a statistically significant difference in DFS between the 2 groups (Fig. 2). It revealed that patients in the high-SII group had worse DFS compared with those in the low-SII group.

### Nomogram and a web-based probability calculator for prognosis of patients with colon cancer undergoing radical surgery

For DFS, the independent risk factors of DFS according to the results of multivariate analysis, including age, tumor location, pathological N stage, and preoperative SII level, were uploaded into the R software to draw a nomogram (Fig. 3). Bootstrap method was applied for internal validation of the nomogram ( $B = 1000$ ) and the C-index was 0.717 (95% CI: 0.654–0.779). The ROC curve indicated that the nomogram had a good ability to predict DFS in a 3-year perspective. Furthermore, the calibration curve derived by the nomogram showed that the probability of DFS agreed well with the actual condition. Both curves are shown in Fig. 4. Moreover, a dynamic web-based probability calculator (<https://medicalclimbers.shinyapps.io/DynNomapp/>) was created to predict the DFS of patients with colon cancer undergoing radical resection according to the nomogram; this web-based probability calculator also made calculation of DFS probability of a single patient easier. As in the example below, it was easy to obtain the DFS probability of a patient by entering the age, tumor location, SII and pathological N stage in the calculator. For example, the 2-year DFS probability of patients who were


**Fig. 2.** Survival analysis of SII according to the Kaplan–Meier method

SII – systemic immune-inflammatory index; DFS – disease-free survival.

**Table 3.** Univariate and multivariate Cox regression analysis of DFS in patients with colon cancer

Variables	Variables	Univariate analysis		Multivariate analysis	
		HR (95% CI)	p-value	HR (95% CI)	p-value
Age [years]	<65	1 (reference)	0.016	1 (reference)	0.001
	≥65	1.956 (1.131–3.384)		2.581 (1.465–4.549)	
Preoperative CEA [ng/mL]	<5	1 (reference)	0.008	–	–
	≥5	2.049 (1.209–3.472)		–	
Tumor location	left colon	1 (reference)	0.015	1 (reference)	0.000
	right colon	1.849 (1.126–3.037)		2.535 (1.509–4.258)	
Vascular invasion	yes	1 (reference)	0.033	–	–
	none	1.733 (1.045–2.875)		–	
Nerve invasion	yes	1 (reference)	0.064	–	–
	none	1.762 (0.968–3.206)		–	
N stage	0	1 (reference)	0.000	1 (reference)	0.000
	1	2.162 (1.202–3.886)		3.031 (1.648–5.575)	
	2	4.442 (2.361–8.358)		6.222 (3.214–12.045)	
TNM stage	I (including T0)	1 (reference)	0.001	–	–
	II	2.261 (0.304–16.809)		–	
	III	5.690 (0.782–41.378)		–	
SII	low group	1 (reference)	0.051	1 (reference)	0.040
	high group	1.654 (0.998–2.741)		1.708 (1.025–2.844)	

DFS – disease-free survival; HR – hazard ratio; 95% CI – 95% confidence interval; CEA – carcinoembryonic antigen; SII – systemic immune-inflammation index.

**Fig. 3.** Nomogram for predicting 1-, 2- and 3-year DFS after radical resection of colon cancer

SII – systemic immune- inflammation index; DFS – disease-free survival.

65 years old or older and had left-sided colon cancer, high preoperative SII and pathological N1 stage was about 65% (95% CI: 50–83%) (Fig. 5).

## Discussion

Tumor-associated inflammation plays a vital role in the occurrence and development of tumors, and inflammatory and immune cells are important components of the tumor microenvironment.<sup>12</sup> When tissues are injured or infected, the local immune system activates numerous inflammatory cells, such as neutrophils, lymphocytes, macrophages, etc. which secrete a variety of cytokines to form an inflammatory microenvironment and repair

damaged tissues. However, when such inflammatory microenvironment appears in tumor patients, a large number of inflammatory mediators which could alter the internal environment will be released, resulting in a cascade of inflammation-associated reactions. The constant inflammatory microenvironment could lead to the occurrence of tumors, which in turn further aggravate the inflammatory response by tumor formation and development.<sup>13–15</sup> Currently, it is widely believed that tumor-related inflammation suppresses tumor immunity by recruiting regulatory T cells and activating chemokines, leading to tumor progression.<sup>16</sup> Neutrophils inhibit the anti-tumor T response and release pro-angiogenic factors to stimulate the spread of tumor cells, while platelets also secrete a variety of angiogenic factors and tumor growth factors to stimulate the proliferation






Fig. 4. A. ROC curve of the nomogram for predicting 1-, 2- and 3-year DFS after radical resection of colon cancer; B–D. Calibration curves of nomogram for predicting 1-, 2- and 3-year DFS after radical resection of colon cancer

ROC – receiver operating characteristic; AUC – area under curve; DFS – disease-free survival.

and distant metastasis of cancer cells.<sup>4,17</sup> On the other hand, lymphocytes are involved in anti-tumor immunity, triggering tumor apoptosis and necrosis mechanisms, so the decrease in the number of peripheral lymphocytes represents impaired cellular immunological dysfunction.<sup>18–20</sup>

The blood routine is a low-cost, low-trauma and highly repetitive examination procedure both for patients' admitted to hospitals and in outpatient clinics. Due to this, a series of inflammation-related indicators have been studied more intensively, and some of them have been proven to be useful in the prognosis of colon cancer. Catal et al. found that the preoperative PLR value showed good specificity and sensitivity for predicting lymph node metastasis in patients with colon cancer.<sup>21</sup> The study by Turri et al. indicated that patients with stage I or II colon cancer had worse OS when preoperative NLR was greater than 3 ( $p = 0.007$ ).<sup>22</sup> Facciorusso et al. proved that LMR could predict OS and time to recurrence (TTR) in patients with colorectal liver metastasis after radiofrequency ablation.<sup>23</sup> Patients with

LMR  $\leq 3.96\%$  had a shorter median OS (34 months compared to 38 months,  $p = 0.007$ ) and TTR (25 months compared to 35 months,  $p = 0.02$ ) than those with LMR  $> 3.96\%$ . In this study, SII is based on the comprehensive indicators of neutrophils, platelets and lymphocytes, which might better reflect the relationship between immunity and inflammation. The SII is effective in predicting the prognosis of cancers such as gastric cancer,<sup>14</sup> bladder cancer<sup>9</sup> and others. However, there are few studies regarding SII and colon cancer, and there is a lack of unified conclusion on the threshold value of SII. According to relevant studies, between 40% and 50% of patients with colorectal cancer will experience local tumor recurrence or metastasis, which ultimately leads to death.<sup>24,25</sup> Thus, it is necessary to assess the risk of recurrence of patients with colon cancer and take steps as early as possible in order to improve the survival rate and the quality of life. In recent years, many experts have studied the risk factors for recurrence of colon cancer. Some found that with the increase of age,

Dynamic Nomogram




Fig. 5. A web-based probability calculator. When a patient was 65 years old or older and had left-sided colon cancer, high preoperative SII and pathological N1 stage, it showed a rough range of probability of 2-year DFS and its 95% confidence interval (95% CI)

the number of lymphocytes in the body decreases, so SII would increase with age, which may lead to a correlation between age and postoperative recurrence rates.<sup>26</sup> Mizuno et al.<sup>27</sup> confirmed that preoperative CEA level was significant for the prognosis of patients with stage II/III colon cancer, while some other investigators<sup>28</sup> pointed out that postoperative CEA, rather than preoperative CEA, could more accurately predict the probability of recurrence and death after operation. This dispute warrants more studies in the future. In addition, Lee et al. found that left colon cancer patients had considerably better DFS and OS compared with those with right colon affected, which might be due to the different biologic characteristics of colon cancer at different location.<sup>29</sup> Saha et al. found that tumor

diameter negatively impacted survival, whereas our study failed to confirm the connection between tumor diameter and prognosis because of the small sample size.<sup>30</sup> Nevertheless, other classic factors, such as pathological N stage,<sup>31</sup> were proven to be related to DFS. A meta-analysis confirmed that higher preoperative SII level could predict worse DFS of patients with colon cancer, which is in accordance with our study.<sup>4</sup> However, the cutoff value of SII was not standardized in general. In our study, the cutoff value of SII was 514.13, which is similar to the findings presented in other studies, where the cutoff SII ranged from 340 to 667.75.<sup>10,32,33</sup> The varied values of SII do not alter our conclusion; however, the optimal cutoff value still needs to be adjusted according to clinical



practice. Despite the fact that the TNM analysis can predict the prognosis of patients with cancers, its limited accuracy results in heterogeneity of patients with the same stage.<sup>34</sup> Some research has put forward several new TNM staging strategies to predict the prognosis of patients with colorectal cancer.<sup>35–37</sup> Therefore, the nomogram in this study could integrate various clinical information to provide more accurate and individualized prognostic prediction, better than just TNM stage. Furthermore, the nomogram established here is based on independent risk factors that could well predict DFS of patients with colon cancer 1, 2 and 3 years after surgery. To be more exact, we were able to predict the probability of 1-, 2- and 3- DFS of patients with colon cancer based on their clinical characteristics including age, tumor location, preoperative SII, and N stage.

Inflammatory response is not the only factor affecting the prognosis of patients with cancers. Nowadays, more attention has been paid to tumor drug therapies like chemotherapy and immunotherapy, while surgical treatment seems less important. While all cases in this study received radical surgery, the prognosis of patients may be influenced by many factors, including different surgical methods and experience of operators. A meta-analysis of 16 retrospective studies showed that any complication after radical surgery in patients for stage II and III gastric cancer predicted a poor outcome, while the same result was not found in patients with stage I gastric cancer.<sup>38</sup> For functional well-differentiated neuroendocrine tumors (NETs) with liver metastases, surgery is not usually the first choice. However, Citterio et al. demonstrated that resection of the primary tumor might improve the survival in these patients.<sup>39</sup> For pancreatic cancer, radical surgery is still the only curative method, but the choice of surgical method is worth further discussion. The survival benefits of patients with pancreatic head cancer were not significantly improved by extended resection when compared with standard pancreaticoduodenectomy. Conversely, better survival outcomes were achieved by extended resection of pancreatic tail or body cancer.<sup>40</sup> For colon cancer, the choice between open and laparoscopic surgery has always been controversial. Mazaki et al. found that compared with colon cancer patients who underwent open radical surgery, those who received laparoscopic radical surgery had a lower 5-year cumulative local recurrence rate (9.2% compared to 0%,  $p = 0.007$ ), but the 5-year distant metastasis rate seemed to be higher (9.2% compared to 12.7%,  $p = 0.49$ ).<sup>41</sup> In summary, future studies should also pay more attention to tumor surgical treatment, such as the timing of surgery, the choice of surgical methods and postoperative complications, so as to provide reference for prolonging the survival of patients.

## Limitations

Inevitably, there were some limitations of this study. Firstly, it was a single-center retrospective study with a small sample size and some loss of clinical data, which

had selection bias, confounding bias and some other drawbacks. Additionally, the differing surgical experience of the operators could also lead to differences in the postoperative tumor recurrence rate of patients. This nomogram had only been verified internally due to limitations imposed due to COVID-19 pandemic and small sample size. As a result, its reliability was weaker when it was verified in different cohorts. Although our study lacked external validation, the nomogram performed well in terms of discrimination and calibration, and it predicted the probability of disease-free survival 1, 2 and 3 years after radical surgery, which was rarely performed in other studies. Future studies should collect data from other centers for external validation. Finally, factors related to prognosis such as microsatellite instability, KRAS and NRAS<sup>42</sup> mutations, and the question whether to perform postoperative adjuvant therapy were not included in the study. Meanwhile, whether SII has predictive value for patients of all races, regions and types requires more multicenter and larger sample research in the future.

## Conclusion

In summary, this study found that SII, as a novel prognostic indicator based on inflammation in recent years, could independently predict the postoperative recurrence of patients with colon cancer. The nomogram based on SII and other independent factors could effectively predict 1-, 2- and 3-year DFS of patients after surgery, providing patients and doctors with more accurate and timely prognostic judgments, which could potentially improve survival rate and quality of life. Moreover, a dynamic web-based probability calculator constructed according to the nomogram made it easier and more convenient to predict the prognosis of patients in clinical work.

## ORCID iDs

Lu Zhang  <https://orcid.org/0000-0003-2065-2287>  
 Zhong Zhang  <https://orcid.org/0000-0002-5605-4951>  
 Haochun Guo  <https://orcid.org/0000-0002-6742-6634>  
 Bin Huang  <https://orcid.org/0000-0002-7738-3455>  
 Haijun Zhang  <https://orcid.org/0000-0002-4313-3001>

## References

1. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin.* 2021;71(3):209–249. doi:10.3322/caac.21660
2. Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): Analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. *Lancet.* 2018; 391(10125):1023–1075. doi:10.1016/S0140-6736(17)33326-3
3. National Cancer Center, China, Expert Group of the Development of China Guideline for the Screening, Early Detection and Early Treatment of Colorectal Cancer. China Guideline for the Screening, Early detection and Early Treatment of Colorectal Cancer (2020, Beijing) [in Chinese]. *Zhonghua Zhong Liu Za Zhi.* 2021;43(1):16–38. doi:10.3760/cma.j.cn112152-20210105-00010

4. Yang R, Chang Q, Meng X, Gao N, Wang W. Prognostic value of systemic immune-inflammation index in cancer: A meta-analysis. *J Cancer*. 2018;9(18):3295–3302. doi:10.7150/jca.25691
5. Park BK, Park JW, Han EC, et al. Systemic inflammatory markers as prognostic factors in stage IIA colorectal cancer. *J Surg Oncol*. 2016;114(2):216–221. doi:10.1002/jso.24299
6. Trinh H, Dzul SP, Hyder J, et al. Prognostic value of changes in neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR) and lymphocyte-to-monocyte ratio (LMR) for patients with cervical cancer undergoing definitive chemoradiotherapy (dCRT). *Clin Chim Acta*. 2020;510:711–716. doi:10.1016/j.cca.2020.09.008
7. Fu S, Yan J, Tan Y, Liu D. Prognostic value of systemic immune-inflammation index in survival outcome in gastric cancer: A meta-analysis. *J Gastrointest Oncol*. 2021;12(2):344–354. doi:10.21037/jgo-20-252
8. Zhang Y, Sun Y, Zhang Q. Prognostic value of the systemic immune-inflammation index in patients with breast cancer: A meta-analysis. *Cancer Cell Int*. 2020;20(1):224. doi:10.1186/s12935-020-01308-6
9. Zhang W, Wang R, Ma W, et al. Systemic immune-inflammation index predicts prognosis of bladder cancer patients after radical cystectomy. *Ann Transl Med*. 2019;7(18):431. doi:10.21037/atm.2019.09.02
10. Rimini M, Casadei-Gardini A, Ravaioli A, et al. Could inflammatory indices and metabolic syndrome predict the risk of cancer development? Analysis from the Bagnacavallo Population Study. *J Clin Med*. 2020;9(4):1177. doi:10.3390/jcm9041177
11. Kornprat P, Pollheimer MJ, Lindtner RA, Schlemmer A, Rehak P, Langner C. Value of tumor size as a prognostic variable in colorectal cancer: A critical reappraisal. *Am J Clin Oncol*. 2011;34(1):43–49. doi:10.1097/COC.0b013e3181cae8dd
12. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. *Cell*. 2011;144(5):646–674. doi:10.1016/j.cell.2011.02.013
13. Shi H, Jiang Y, Cao H, Zhu H, Chen B, Ji W. Nomogram based on systemic immune-inflammation index to predict overall survival in gastric cancer patients. *Dis Markers*. 2018;2018:1787424. doi:10.1155/2018/1787424
14. Grivninkov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. *Cell*. 2010;140(6):883–899. doi:10.1016/j.cell.2010.01.025
15. Duan R, Nilsson A. Metabolism of sphingolipids in the gut and its relation to inflammation and cancer development. *Prog Lipid Res*. 2009;48(1):62–72. doi:10.1016/j.plipres.2008.04.003
16. Caronni N, Savino B, Bonocchi R. Myeloid cells in cancer-related inflammation. *Immunobiology*. 2015;220(2):249–253. doi:10.1016/j.imbio.2014.10.001
17. Swierczak A, Mouchemore KA, Hamilton JA, Anderson RL. Neutrophils: Important contributors to tumor progression and metastasis. *Cancer Metastasis Rev*. 2015;34(4):735–751. doi:10.1007/s10555-015-9594-9
18. Ivanova OK, Sharapova TN, Romanova EA, Soshnikova NV, Sashchenko LP, Yashin DV. CD3<sup>+</sup> CD8<sup>+</sup> NKG2D<sup>+</sup> T lymphocytes induce apoptosis and necroptosis in HLA-negative cells via FasL–Fas interaction. *J Cell Biochem*. 2017;118(10):3359–3366. doi:10.1002/jcb.25990
19. Dudani S, Marginean H, Tang PA, et al. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictive and prognostic markers in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiation. *BMC Cancer*. 2019;19(1):664. doi:10.1186/s12885-019-5892-x
20. Ksienski D, Wai ES, Alex D, et al. Prognostic significance of the neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio for advanced non-small cell lung cancer patients with high PD-L1 tumor expression receiving pembrolizumab. *Transl Lung Cancer Res*. 2021;10(1):355–367. doi:10.21037/tlcr-20-541
21. Catal O, Ozer B, Sit M. Prediction of lymph node metastasis in colon cancer via platelet to lymphocyte ratio and platelet count. *J Coll Physicians Surg Pak*. 2020;30(3):250–253. doi:10.29271/jcpsp.2020.03.250
22. Turri G, Barresi V, Valdegamberi A, et al. Clinical significance of preoperative inflammatory markers in prediction of prognosis in node-negative colon cancer: Correlation between neutrophil-to-lymphocyte ratio and poorly differentiated clusters. *Biomedicines*. 2021;9(1):94. doi:10.3390/biomedicines9010094
23. Facciorusso A, Prete VD, Crucinio N, Serviddio G, Vendemiale G, Muscatello N. Lymphocyte-to-monocyte ratio predicts survival after radiofrequency ablation for colorectal liver metastases. *World J Gastroenterol*. 2016;22(16):4211–4218. doi:10.3748/wjg.v22.i16.4211
24. Osterman E, Hammarström K, Imam I, Osterlund E, Sjöblom T, Glimelius B. Completeness and accuracy of the registration of recurrences in the Swedish Colorectal Cancer Registry (SCRCR) and an update of recurrence risk in colon cancer. *Acta Oncol*. 2021;60(7):842–849. doi:10.1080/0284186X.2021.1896033
25. Benitez Majano S, Di Girolamo C, Rachet B, et al. Surgical treatment and survival from colorectal cancer in Denmark, England, Norway, and Sweden: A population-based study. *Lancet Oncol*. 2019;20(1):74–87. doi:10.1016/S1470-2045(18)30646-6
26. Macedo Queiroz Mota Castellão Tavares S, de Lima Bravo Junior Jr., Ribeiro Lopes e Silva M. Normal lymphocyte immunophenotype in an elderly population. *Rev Bras Hematol Hemoter*. 2014;36(3):180–183. doi:10.1016/j.bjhh.2014.03.021
27. Mizuno H, Miyake H, Nagai H, et al. Optimal cutoff value of preoperative CEA and CA19-9 for prognostic significance in patients with stage II/III colon cancer. *Langenbecks Arch Surg*. 2021;406(6):1987–1997. doi:10.1007/s00423-021-02236-3
28. Kwaan MR. Postoperative CEA and other non-traditional risk factors for colon cancer recurrence: Findings from Swedish population-based data. *Ann Surg Oncol*. 2020;27(4):971–972. doi:10.1245/s10434-019-08151-8
29. Lee MS, Menter DG, Kopetz S. Right versus left colon cancer biology: Integrating the consensus molecular subtypes. *J Natl Compr Canc Netw*. 2017;15(3):411–419. doi:10.6004/jnccn.2017.0038
30. Saha S, Shaik M, Johnston G, et al. Tumor size predicts long-term survival in colon cancer: An analysis of the National Cancer Data Base. *Am J Surg*. 2015;209(3):570–574. doi:10.1016/j.amjsurg.2014.12.008
31. Osterman E, Mezheyeuski A, Sjöblom T, Glimelius B. Beyond the NCCN risk factors in colon cancer: An evaluation in a Swedish population-based cohort. *Ann Surg Oncol*. 2020;27(4):1036–1045. doi:10.1245/s10434-019-08148-3
32. Chen JH, Zhai ET, Yuan YJ, et al. Systemic immune-inflammation index for predicting prognosis of colorectal cancer. *World J Gastroenterol*. 2017;23(34):6261–6272. doi:10.3748/wjg.v23.i34.6261
33. Tao MY, Wang ZH, Zhang MH, et al. Prognostic value of the systematic immune-inflammation index among patients with operable colon cancer: A retrospective study. *Medicine (Baltimore)*. 2018;97(45):e13156. doi:10.1097/MD.00000000000013156
34. Mo S, Zhou Z, Li Y, et al. Establishment and validation of a novel nomogram incorporating clinicopathological parameters into the TNM staging system to predict prognosis for stage II colorectal cancer. *Cancer Cell Int*. 2020;20(1):285. doi:10.1186/s12935-020-01382-w
35. Ogawa S, Itabashi M, Bamba Y, et al. Stage II colon cancer staging using the number of retrieved lymph nodes may be superior to current TNM staging for prognosis stratification: The Japanese study group for postoperative follow-up of colorectal cancer. *Int J Colorectal Dis*. 2021;36(10):2205–2214. doi:10.1007/s00384-021-03990-y
36. Shinto E, Hida JI, Ike H, et al. A new N staging system for colorectal cancer in the era of extended lymphadenectomy. *Ann Surg Oncol*. 2018;25(13):3891–3897. doi:10.1245/s10434-018-6786-x
37. Arabiki M, Shimada Y, Nakano M, et al. Verification of the Japanese staging system for rectal cancer, focusing on differences with the TNM classification. *Surg Today*. 2020;50(11):1443–1451. doi:10.1007/s00595-020-02024-4
38. Wang S, Xu L, Wang Q, et al. Postoperative complications and prognosis after radical gastrectomy for gastric cancer: A systematic review and meta-analysis of observational studies. *World J Surg Oncol*. 2019;17(1):52. doi:10.1186/s12957-019-1593-9
39. Citterio D, Pusceddu S, Facciorusso A, et al. Primary tumour resection may improve survival in functional well-differentiated neuroendocrine tumours metastatic to the liver. *Eur J Surg Oncol*. 2017;43(2):380–387. doi:10.1016/j.ejso.2016.10.031
40. Cheol Kim S, Hoon Kim Y, Min Park K, Ju Lee Y. Pancreatic cancer surgery: The state of the art. *Curr Drug Targets*. 2012;13(6):764–771. doi:10.2174/138945012800564185
41. Mazaki J, Katsumata K, Tago T, et al. Long-term outcomes of laparoscopic versus open surgery for colon cancer in noncancer-specific hospital: Propensity score analysis. *J Laparoendosc Adv Surg Tech A*. 2021;31(4):433–442. doi:10.1089/lap.2020.0510
42. Dienstmann R, Mason MJ, Sinicrope FA, et al. Prediction of overall survival in stage II and III colon cancer beyond TNM system: A retrospective, pooled biomarker study. *Ann Oncol*. 2017;28(5):1023–1031. doi:10.1093/annonc/mdx052